Sabal Trust CO purchased a new stake in Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,237 shares of the biopharmaceutical company’s stock, valued at approximately $412,000.
Other hedge funds have also modified their holdings of the company. Huntington National Bank boosted its stake in shares of Shire PLC by 1,578.3% in the second quarter. Huntington National Bank now owns 17,135 shares of the biopharmaceutical company’s stock valued at $3,154,000 after buying an additional 16,114 shares during the period. Johnston Asset Management LLC boosted its stake in shares of Shire PLC by 80.8% in the second quarter. Johnston Asset Management LLC now owns 131,109 shares of the biopharmaceutical company’s stock valued at $24,135,000 after buying an additional 58,607 shares during the period. Northern Capital Management LLC boosted its stake in shares of Shire PLC by 14.5% in the second quarter. Northern Capital Management LLC now owns 15,790 shares of the biopharmaceutical company’s stock valued at $2,907,000 after buying an additional 1,995 shares during the period. Clean Yield Group purchased a new stake in shares of Shire PLC during the second quarter valued at $792,000. Finally, Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in shares of Shire PLC during the second quarter valued at $674,000. 24.26% of the stock is currently owned by institutional investors and hedge funds.
Shire PLC (NASDAQ:SHPG) traded down 0.43% during midday trading on Tuesday, reaching $194.59. The company’s stock had a trading volume of 825,150 shares. Shire PLC has a 1-year low of $147.60 and a 1-year high of $231.32. The company’s 50-day moving average price is $196.04 and its 200-day moving average price is $186.49. The company has a market capitalization of $57.96 billion, a price-to-earnings ratio of 40.44 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The business had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The business’s revenue was up 55.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.63 EPS. On average, analysts predict that Shire PLC will post $12.92 earnings per share for the current fiscal year.
The company also recently declared a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be given a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
Several brokerages recently weighed in on SHPG. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Shire PLC in a report on Monday. Leerink Swann reiterated a “buy” rating on shares of Shire PLC in a research note on Saturday. Piper Jaffray Cos. set a $201.00 price target on shares of Shire PLC and gave the company a “hold” rating in a research note on Saturday. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research note on Wednesday, September 28th. Finally, Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, September 27th. Five equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. Shire PLC currently has an average rating of “Buy” and a consensus target price of $232.75.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.